Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Dermatology

Daily Skin Care & Treatment Safety

At a Glance

In Netherton syndrome, daily bathing and frequent fragrance-free moisturizing help support the fragile skin barrier, but creams can enter the bloodstream more easily than usual. Use topical medicines only under an individualized specialist plan, with monitoring when needed.

Managing the skin in Netherton syndrome is a delicate balancing act. Because the LEKTI protein is missing, the skin barrier is highly permeable. This means it acts like a sponge for anything applied to it [1][2]. This makes daily supportive care the foundation of treatment, while also creating serious risks for common medical creams.

The Foundation: Daily Supportive Care

The goal of daily care is to manually support the barrier that the body cannot maintain on its own.

  • Bathing and Emollients: Regular bathing followed by the generous and frequent application of fragrance-free emollients (moisturizers) is essential [3]. These help trap moisture and provide a mechanical shield. Emollients should be chosen carefully with your team to avoid stinging or irritation on inflamed skin, and applied immediately after bathing [4].
  • Infection Prevention: Because the skin barrier is broken, children with Netherton syndrome are prone to infections [5]. Suspected bacterial, viral, or fungal infections require assessment by a clinician who can prescribe targeted treatments, sometimes guided by a skin culture. Do not use over-the-counter antiseptics or add them to baths without explicit guidance from your treating team, as this can worsen irritation or lead to unsafe absorption [6].
  • Monitoring Growth: The skin uses immense energy trying to repair itself [6]. Consistent tracking of height and weight is a standard part of care to ensure the child is growing adequately despite the metabolic demands of the skin condition [7][8].

The Critical Warning: Topical Treatment Safety

In most skin conditions, topical corticosteroids or calcineurin inhibitors (like tacrolimus) stay on the surface. In Netherton syndrome, these medications can pass directly through the defective barrier and enter the bloodstream at much higher levels [9][1].

The Risk of Systemic Absorption:

  • Topical Corticosteroids: When used extensively or for prolonged periods, enhanced absorption can cause systemic side effects like Cushing syndrome (weight gain, a rounded face) or adrenal suppression, where the body stops making its own vital stress hormones [9][10]. Tapering and cortisol testing may be required under specialist direction to safely manage this risk.
  • Tacrolimus and Pimecrolimus: These “steroid-free” creams can also be absorbed systemically. While they may be used under careful specialist direction, laboratory testing of blood levels is sometimes used selectively to ensure they do not reach toxic amounts [2][1].

Safe Usage Principles:

  1. Individualized Plans: There is no universal “safe limit” that applies to everyone. You must follow an individualized written plan from a Netherton-experienced clinician detailing the potency, area, duration, and formulation of any medication.
  2. No Unsupervised Changes: Do not start, stop, or abruptly change the use of any topical steroid or over-the-counter product without consulting your care team. Sudden cessation of a long-term steroid can trigger an adrenal crisis [8].

Systemic Therapies

Because of the risks of topical treatments, specialists may consider systemic therapies (medications that work throughout the body).

  • Dupilumab: This biologic medication has shown promise in small, case-based studies for improving inflammation, itching, and quality of life in some Netherton patients [11][12]. However, responses are not uniformly complete, and it is still being studied [13][14].
  • Other Off-Label Treatments: Medications like IVIG or other biologics have been tried in small case reports, but they are not routine choices and evidence for their efficacy remains very low [15][14]. Always discuss the specific evidence and required monitoring for any systemic therapy with your multidisciplinary team.

Common questions in this guide

What daily skin-care routine helps children with Netherton syndrome?
Regular bathing followed immediately by generous, frequent use of a fragrance-free emollient can help retain moisture and support the skin barrier. Choose products with your care team, especially if the skin is inflamed or stings easily.
Why can medicated creams be risky in Netherton syndrome?
The defective skin barrier can allow topical medicines to enter the bloodstream at higher levels than expected. Extensive or prolonged use of topical steroids may cause problems such as Cushing syndrome or reduced adrenal hormone production, while tacrolimus and pimecrolimus can also be absorbed and may need specialist monitoring.
Can we stop a topical steroid suddenly?
Do not start, stop, or substantially change a topical steroid without advice from the treating team. Abruptly stopping a steroid used for a long time can contribute to an adrenal crisis, so the clinician may provide a tapering plan and arrange cortisol testing when appropriate.
How can I tell whether a flare is an infection?
Children with Netherton syndrome are prone to bacterial, viral, and fungal skin infections, which can be difficult to distinguish from a usual flare at home. Contact a clinician for assessment; a skin culture may help guide treatment, and over-the-counter antiseptics should not be used or added to baths without explicit medical guidance.
Could dupilumab help my child with Netherton syndrome?
Dupilumab has improved inflammation, itching, and quality of life in some people with Netherton syndrome in small case-based studies. Results are not always complete, and the treatment remains under study, so a specialist should decide whether it is appropriate and explain the monitoring and expected benefits.
What monitoring may be needed during treatment?
Regular height and weight checks help make sure a child is growing adequately. Depending on the medicines used, the specialist may also consider blood levels for tacrolimus or pimecrolimus and morning cortisol testing to look for effects from steroid absorption.

Get notified when new evidence is published on Netherton syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Ichthyosis linearis circumflexa in a child. Response to narrowband UVB therapy.

    Singer R, Çopur M, Yüksel EN, et al.

    Journal of dermatological case reports 2015; (9(4)):110-2 doi:10.3315/jdcr.2015.1214.

    PMID: 26848320
  2. 2

    Netherton syndrome with ichthyosis linearis circumflexa and trichorrhexis invaginatum.

    Ng E, Hale CS, Meehan SA, Cohen DE

    Dermatology online journal 2014; (20(12)).

    PMID: 25526335
  3. 3

    Netherton Syndrome: A Comprehensive Literature Review of Pathogenesis, Clinical Manifestations, and Therapeutic Strategies.

    Mocarska M, Muciek A, Dolinkiewicz J, et al.

    Journal of mother and child 2025; (29(1)):106-113 doi:10.34763/jmotherandchild.20252901.d-25-00014.

    PMID: 40899446
  4. 4

    Netherton Syndrome Perspectives.

    Hon KLE, Cheung YC, Chan ZM, et al.

    Current pediatric reviews 2025; doi:10.2174/0115733963361849250611072347.

    PMID: 40551686
  5. 5

    A Case Report on Netherton Syndrome.

    Abdalrheem WO, Alluhayyan OB, Alharbi A

    Cureus 2020; (12(7)):e9166 doi:10.7759/cureus.9166.

    PMID: 32802603
  6. 6

    Netherton Syndrome in Thai Children: A Report of Two Cases With a Literature Review.

    Temboonnark P, Daengsuwan T

    Cureus 2024; (16(6)):e62718 doi:10.7759/cureus.62718.

    PMID: 39036217
  7. 7

    Severe Hypernatremia as Presentation of Netherton Syndrome.

    Di Nora A, Consentino MC, Messina G, et al.

    Global medical genetics 2023; (10(4)):335-338 doi:10.1055/s-0043-1776983.

    PMID: 38025195
  8. 8

    Topical glucocorticoid application causing iatrogenic Cushing's syndrome followed by secondary adrenal insufficiency in infants: two case reports.

    Matejek N, Hoos J, Holterhus PM, et al.

    Journal of medical case reports 2022; (16(1)):455 doi:10.1186/s13256-022-03659-2.

    PMID: 36476353
  9. 9

    [Fatal outcome of Netherton syndrome due to excessive use of topical corticosteroids in an adult patient].

    Valette C, Ofaiche J, Severino M, Mazereeuw-Hautier J

    Annales de dermatologie et de venereologie 2020; (147(1)):36-40 doi:10.1016/j.annder.2019.09.003.

    PMID: 31653452
  10. 10

    Persistent methicillin-resistant Staphylococcus aureus bacteremia in an adult patient with Netherton's syndrome: A case report.

    Takahashi M, Hagiya H, Tanaka S, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2022; (28(7)):978-981 doi:10.1016/j.jiac.2022.02.021.

    PMID: 35277342
  11. 11

    Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.

    Yan S, Wu X, Jiang J, et al.

    Frontiers in immunology 2022; (13()):1054422 doi:10.3389/fimmu.2022.1054422.

    PMID: 36569942
  12. 12

    Beyond Eczema Control: Long-Term Outcomes of Dupilumab Therapy in Six Patients with Netherton Syndrome.

    Zawadzińska-Halat K, Stec M, Poznańska-Kurowska K, Pastuszczak M

    Biologics : targets & therapy 2026; (20()):638248 doi:10.2147/BTT.S638248.

    PMID: 42890707
  13. 13

    Long-term dupilumab therapy in Netherton syndrome with severe atopic manifestations: Case report and review of the literature.

    Özkaya E, Günay MB, Babuna Kobaner G, et al.

    The Australasian journal of dermatology 2023; (64(2)):272-277 doi:10.1111/ajd.13986.

    PMID: 36745433
  14. 14

    Outcomes of Systemic Treatment in Children and Adults With Netherton Syndrome: A Systematic Review.

    Nouwen AEM, Schappin R, Nguyen NT, et al.

    Frontiers in immunology 2022; (13()):864449 doi:10.3389/fimmu.2022.864449.

    PMID: 35464459
  15. 15

    Treatment Experiences with Intravenous Immunoglobulins, Ixekizumab, Dupilumab, and Anakinra in Netherton Syndrome: A Case Series.

    Ragamin A, Nouwen AEM, Dalm VASH, et al.

    Dermatology (Basel, Switzerland) 2023; (239(1)):72-80 doi:10.1159/000525987.

    PMID: 35998563

This page is for informational purposes only and does not constitute medical advice about Netherton syndrome. Your child's dermatologist and treating team should individualize every skin-care product, medication, and monitoring plan.